Celladon, which is developing novel therapies for the treatment of heart disease, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Celladon would command a market value of $257 million.
Celladon, which was founded in 2000, plans to list on the NASDAQ under the symbol CLDN. Celladon initially filed confidentially on September 6, 2013. J.P. Morgan and Barclays are the joint bookrunners on the deal.
